Page 3 - Lexaria Bioscience News Today

Right now, there is nothing that is earthmoving. That is a great way to lead off the show. I have unbelievable stuff. Okay. Lets get to our road map this morning. It does start with apples ev aboutface, reportedly abandoning its decadeslong efforts to develop an automobile, turning its focus to generative a. I. Shares have underperformed so far this year. Continued signs of a robust economy, healthy Consumer Spending certainly one reason why and goldmans ceo thinks a soft landing is uncertain. A...

Stocks not doing much. Revenue forecast, certainly concerning. Well talk to jim a lot about that, and well talk a lot about snowflake. That stock is down dramatically this morning, both on guidance and the news that its ceo, Frank Slootman, will be retiring. Suboptimal. Yeah. Suboptimal. Lets start with the inflation data, sort of get that out of the way before we move on. Whats your take on this pce number . In line is cool. Thats the way i look at it. I think that there were a lot of people wh...

For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral formatKELOWNA, BC / ACCESSWIRE / May 23, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company"

KELOWNA, BC / ACCESSWIRE / May 21, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces two important new patent

Cowen AND Company LLC purchased a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 256,327 shares of the company’s stock, valued at approximately $320,000. Cowen AND Company LLC owned about 2.46% of […]

Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) – Research analysts at Zacks Small Cap lifted their FY2024 earnings estimates for shares of Lexaria Bioscience in a research report issued on Monday, April 29th. Zacks Small Cap analyst J. Vandermosten now anticipates that the company will earn ($0.46) per share for the year, up from their […]

Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise ...

Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery. GLP-1 drugs, like semaglutide, are currently delivered through...

Insiders were net buyers of Lexaria Bioscience Corp.'s ( NASDAQ:LEXX ) stock during the past year. That is, insiders...